On ImmunoGen and Mirvetuximab Soravtansine (IMGN 853), A Subjective Meta-Analysis From A Clinical Trial Based Perspective | PDF | Ovarian Cancer | Chemotherapy
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text
Mirvetuximab Soravtansine - CancerConnect
Mirvetuximab Combos for Ovarian Cancer Showing Promise in Trials
Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors - Moore - 2017 - Cancer - Wiley Online Library
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect
Antibody drug conjugate: the “biological missile” for targeted cancer therapy | Signal Transduction and Targeted Therapy
Pharmaceuticals | Free Full-Text | Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications | HTML
Mirvetuximab Elicits Responses in More Than 31% of Patients With FRalpha-High Platinum-Resistant Ovarian Cancer | Clearity Foundation
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. - Abstract - Europe PMC
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology
Pharmacokinetic head-to-head comparison between... | Download Scientific Diagram
SORAVTANSINE
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer | Business Wire
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer - Gynecologic Oncology
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine -
Mirvetuximab Soravtansine - CancerConnect
Targeting the folate receptor for the treatment of ovarian cancer - Lutz - Translational Cancer Research
NCT02631876 (Clinical Trial/ MIRVETUXIMAB SORAVTANSINE/ IMGN-853) » ADC Review
Unlocking the potential of antibody–drug conjugates for cancer therapy | Nature Reviews Clinical Oncology
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody- drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer -
